Effectiveness and Cost-effectiveness of Simultaneous Screening and Intervention for Antenatal Depression and Anxiety Symptoms From a Transdiagnostic Perspective: A Scale-up Feasibility Study
1 other identifier
interventional
3,314
1 country
1
Brief Summary
This scale-up study aimed to explore the effectiveness of simultaneous screening and intervention of antenatal depression and anxiety in preventing postpartum depression and anxiety and how scale-up might be successfully achieved. The age was ≥18 years old pregnancy and capable of completing the independent assessment of smart phones. Exclude those with abnormal comprehension and expression abilities. The implementation group, 1. screening during pregnancy and 42 days postpartum; 2. Stratified iCBT Intervention, usual care. Low-intensity: Mild cases (EPDS≥9/GAD-7≥5) received 11 animated video sessions adapted from WHO's Thinking Healthy Programme manual. High-intensity: Moderate-severe cases (EPDS≥12/GAD-7≥10) received low-intensity components and supplemental telehealth counseling. The control group, screening at 42 days postpartum, usual care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 24, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 24, 2022
CompletedFirst Submitted
Initial submission to the registry
December 7, 2025
CompletedFirst Posted
Study publicly available on registry
January 16, 2026
CompletedJanuary 16, 2026
December 1, 2025
1.3 years
December 7, 2025
January 11, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Edinburgh Postnatal Depression Scale (EPDS) Score
The EPDS is a 10-item self-report questionnaire. Total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.
at 42 days postpartum
Generalized Anxiety Disorder 7-item (GAD-7) Scale Score
The GAD-7 is a 7-item self-report questionnaire. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.
at 42 days postpartum
Other Outcomes (1)
cost-effectiveness ratios (ICER)
at 42 days postpartum
Study Arms (2)
usual care group
NO INTERVENTIONno additional intervention
Stratified iCBT group
EXPERIMENTALStratified iCBT(Internet-based Cognitive Behavioral Therapy) Intervention plus usual care
Interventions
1. screening during pregnancy and 42 days postpartum 2. Stratified iCBT Intervention, usual care Low-intensity: Mild cases (EPDS≥9/GAD-7≥5) received 11 animated video sessions adapted from WHO's Thinking Healthy Programme manual. High-intensity: Moderate-severe cases (EPDS≥12/GAD-7≥10) received low-intensity components and supplemental telehealth counseling.
Eligibility Criteria
You may qualify if:
- The age was ≥18 years old pregnancy and capable of completing the independent assessment of smart phones.
You may not qualify if:
- Exclude those with abnormal comprehension and expression abilities
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Jieshou Maternal and Child Health Hospital
Fuyang, China
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 7, 2025
First Posted
January 16, 2026
Study Start
March 24, 2021
Primary Completion
June 24, 2022
Study Completion
June 24, 2022
Last Updated
January 16, 2026
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
This study does not currently plan to share individual participant data (IPD). The main reasons are: ① The study involves sensitive clinical information (e.g., scores from mental health scales), and there remains potential privacy risks even after de-identification; ② The data usage agreement does not include authorization for external sharing, and additional informed consent from study participants is required.